Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746679 | 1.00 | BRAF (0.71) | BRAFMAPK14RAF1YES1 | |
| SCHEMBL4750107 | 0.93 | BRAF (0.66) | BRAFRAF1YES1 | |
| SCHEMBL4749211 | 0.90 | BRAF (0.68) | BRAFRAF1YES1 | |
| SCHEMBL5000815 | 0.90 | BRAF (0.63) | BRAFRAF1YES1 | |
| SCHEMBL5000778 | 0.90 | MAPK14 (0.73) | BRAFMAPK14RAF1YES1 | |
| SCHEMBL4967069 | 0.90 | BRAF (0.62) | BRAFMAPK14RAF1YES1 | |
| SCHEMBL5004339 | 0.90 | BRAF (0.62) | BRAFRAF1YES1 | |
| SCHEMBL4967550 | 0.90 | BRAF (0.67) | BRAFRAF1YES1 | |
| SCHEMBL4747084 | 0.89 | BRAF (0.57) | BRAFMAPK14 | |
| SCHEMBL4750071 | 0.89 | BRAF (0.57) | BRAFMAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4636093-A1 | TARGETING MAPK-ERK PATHWAY FOR ENHANCING NUCLEIC ACID DELIVERY | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (DE) | 2025-10-22 | — | — | EP | claimed |
| US-12421517-B2 | Genetic modification of mammalian cells to confer resistance to CSF1R antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-23 | — | — | US | claimed |
| US-20250009746-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2025-01-09 | — | — | US | claimed |
| US-20250002920-A1 | GENETIC MODIFICATION OF MAMMALIAN CELLS TO CONFER RESISTANCE TO CSF1R ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-02 | — | — | US | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| EP-4422617-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118510505-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2024168146-A1 | BRAF GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| CN-118139621-A | Method for amplifying erythroid precursor cells or erythroblasts and application thereof | 北京大学 | 2024-06-04 | — | — | CN | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| WO-2023076991-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023051685-A1 | METHOD FOR AMPLIFYING ERYTHROID PROGENITORS OR ERYTHROBLASTS, AND APPLICATION THEREOF | 北京大学 | 2023-04-06 | — | — | WO | claimed |
| US-20230060581-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-02 | — | — | US | claimed |
| EP-4103286-A1 | METHOD OF TREATING PANCREATIC CANCER | Cedars-Sinai Medical Center (US) | 2022-12-21 | — | — | EP | claimed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2022072632-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | BRAF 910/4885MAPK14 1683/4885RAF1 369/4885 |
| US-20250009746-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | BRAF, ARAF, RAF1 | BRAF 1/4885MAPK14 437/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.